Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use. (August 2014)

• Record Type: Journal Article
• Authors: Magné, Nicolas; Chargari, Cyrus; Levy, Antonin; Guy, Jean-Baptiste; Merrouche, Yacine; Spano, Jean-Philippe
• Is Part Of: Journal of chemotherapy. Volume 26:Number 4(2014:Aug.)
• Page Start: 253
• Page End: 255
• Publication Date: 2014-08
• Subjects: AIDS, -- Bevacizumab, -- Targeted therapies, -- Toxicity; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1179/1973947813Y.0000000109
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract : Human immunodeficiency virus (HIV) patients have more aggressive presentation of colorectal cancer (CRC) and less favourable outcome. Bevacizumab is an antiangiogenic agent that has emerged as a major drug for metastatic CRC. However, few data are available on the safety of bevacizumab in HIV patients. In the light of a case study, we briefly draw intention on how angiogenesis inhibitors could interact with antiviral tri-therapy.